CoChat

Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy

Bello, Luca, Riguzzi, Pietro, Albamonte, Emilio, Astrea, Guja, Battini, Roberta, Barp, Andrea, Berardinelli, Angela L., Bertini, Enrico S., Brolatti, Noemi, Bruno, Claudio, Corti, Stefania, D’Amico, Adele, D’Angelo, Maria Grazia, Dallavalle, Gianfranco, Liguori, Rocco, Maggi, Lorenzo, Magri, Francesca, Mancuso, Michelangelo, Masson, Riccardo, Mercuri, Eugenio, Minetti, Carlo, Messina, Sonia, Mongini, Tiziana, Musumeci, Olimpia, Nigro, Vincenzo, Pane, Marika, Panicucci, Chiara, Pedemonte, Marina, Pini, Antonella, Politano, Luisa, Previtali, Stefano, Ricci, Federica, Ricci, Giulia, Ruggiero, Lucia, Sansone, Valeria, Siciliano, Gabriele, Trabacca, Antonio, Trucco, Federica, Velardo, Daniele, Pegoraro, Elena, Comi, Giacomo P. · 2025 · Drugs in R&D
Cited by 8

The DOI matches its Crossref record.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40268-025-00512-x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919–28. · DOI · Paper page
  2. McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451–61. https://doi.org/10.1016/S0140-6736(17)32160-8. · DOI · Paper page
  3. Bello L, D’Angelo G, Villa M, et al. Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2020;7(5):786–98. https://doi.org/10.1002/acn3.51046. · DOI
  4. Birnkrant DJ, Bello L, Butterfield RJ, et al. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022;10(4):403–20. https://doi.org/10.1016/S2213-2600(21)00581-6. · DOI
  5. Aartsma-Rus A, Van Deutekom JCT, Fokkema IF, Van Ommen GJB, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006;34(2):135–44. https://doi.org/10.1002/mus.20586. · DOI · Paper page
  6. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447(7140):87–91. https://doi.org/10.1038/nature05756. · DOI · Paper page
  7. Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS ONE. 2013;8(12): e81302. https://doi.org/10.1371/journal.pone.0081302. · DOI · Paper page
  8. Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477–87. https://doi.org/10.1002/mus.24332. · DOI · Paper page
  9. McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–98. https://doi.org/10.1016/S0140-6736(17)31611-2. · DOI · Paper page
  10. McDonald CM, Wu S, Gulati S, et al. Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial (PL5.001). Neurology. 2023. https://doi.org/10.1212/WNL.0000000000202505. · doi:10.1212/wnl.0000000000202505
  11. MDA Clinical & Scientific Conference. Ataluren slows the decline of muscle function in patients with nmDMD: a meta-analysis of three randomized, double-blind, placebo-controlled trials [poster]. https://www.mdaconference.org/abstract-library/ataluren-slows-the-decline-of-muscle-function-in-patients-with-nmdmd-a-meta-analysis-of-three-randomized-double-blind-placebo-controlled-trials/. Accessed 13 May 2025.
  12. Campbell C, Barohn RJ, Bertini E, et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res. 2020;9(14):973–84. https://doi.org/10.2217/cer-2020-0095. · DOI
  13. Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393–403. https://doi.org/10.1016/S1474-4422(24)00036-X. · DOI
  14. Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31(1):332–41. https://doi.org/10.1038/s41591-024-03304-z. · DOI · Paper page
  15. Mercuri E, Osorio AN, Muntoni F, et al. Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis. J Neurol. 2023;270(8):3896–913. https://doi.org/10.1007/s00415-023-11687-1. · doi:10.1007/s00415-023-11687-1
  16. McDonald CM, Henricson EK, Abresch RT, et al. The cooperative international neuromuscular research group Duchenne natural history study: a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48(1):32–54. https://doi.org/10.1002/mus.23807. · DOI · Paper page
  17. Muntoni F, Buccella F, Osorio AN, et al. 395P Age at loss of ambulation in patients with nmDMD from the STRIDE Registry: sensitivity analyses. Neuromuscul Disord. 2024;43(S1):104441.123. https://doi.org/10.1016/j.nmd.2024.07.132. · doi:10.1016/j.nmd.2024.07.132
  18. Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465–72. https://doi.org/10.1212/WNL.0000000000002337. · DOI · Paper page
  19. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347–61. https://doi.org/10.1016/S1474-4422(18)30025-5. · DOI · Paper page
  20. Muntoni F, Signorovitch J, Sajeev G, et al. DMD genotypes and motor function in Duchenne muscular dystrophy: a multi-institution meta-analysis with implications for clinical trials. Neurology. 2023;100(15):e1540–54. https://doi.org/10.1212/WNL.0000000000201626. · DOI · Paper page
  21. Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016;87(4):401–9. https://doi.org/10.1212/WNL.0000000000002891. · DOI · Paper page
  22. Torella A, Zanobio M, Zeuli R, et al. The position of nonsense mutations can predict the phenotype severity: a survey on the DMD gene. PLoS ONE. 2020;15(8): e0237803. https://doi.org/10.1371/journal.pone.0237803. · DOI
  23. Ricotti V, Muntoni F, Voit T. Challenges of clinical trial design for DMD. Neuromuscul Disord. 2015;25(12):932–5. https://doi.org/10.1016/j.nmd.2015.10.007. · doi:10.1016/j.nmd.2015.10.007

Cited by

See all 8

Metadata

Authors
Bello, L., Riguzzi, P., Albamonte, E., Astrea, G., Battini, R., Barp, A., Berardinelli, A. L., Bertini, E. S., Brolatti, N., Bruno, C., Corti, S., D’Amico, A., D’Angelo, M. G., Dallavalle, G., Liguori, R., Maggi, L., Magri, F., Mancuso, M., Masson, R., Mercuri, E., Minetti, C., Messina, S., Mongini, T., Musumeci, O., Nigro, V., Pane, M., Panicucci, C., Pedemonte, M., Pini, A., Politano, L., Previtali, S., Ricci, F., Ricci, G., Ruggiero, L., Sansone, V., Siciliano, G., Trabacca, A., Trucco, F., Velardo, D., Pegoraro, E., & Comi, G. P.
Venue
Drugs in R&D
Published
2025-05-28
Volume
25
Issue
2
Pages
99-106
ISSN
  • 1174-5886
  • 1179-6901
Cited by
8
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy. https://app.cochat.ai/papers/10.1007/s40268-025-00512-x
The paper
Bello, L., Riguzzi, P., Albamonte, E., Astrea, G., Battini, R., Barp, A., Berardinelli, A. L., Bertini, E. S., Brolatti, N., Bruno, C., Corti, S., D’Amico, A., D’Angelo, M. G., Dallavalle, G., Liguori, R., Maggi, L., Magri, F., Mancuso, M., Masson, R., . . . Comi, G. P. (2025). Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy. Drugs in R&D. https://doi.org/10.1007/s40268-025-00512-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.